A Study of PHN-012 in Patients With Advanced Solid Tumors

This study is testing a new cancer drug called PHN-012 in people with advanced colorectal cancer, non-small cell lung cancer, or pancreatic cancer who have already tried standard treatments. **You may be eligible if...** - You have been confirmed to have advanced or metastatic colorectal cancer, non-small cell lung cancer, or pancreatic ductal cancer - You have already tried at least one prior treatment and your cancer has progressed - Your cancer can be measured on imaging scans - Your overall health and organ function meet study requirements (ECOG score of 0 or 1) - You have tumor tissue available for testing **You may NOT be eligible if...** - You have previously been treated with a drug-antibody combination (ADC) that targets a specific enzyme called topoisomerase-1 - You have unstable brain metastases - You have side effects from prior treatment that have not resolved - You have a history of serious lung inflammation (pneumonitis/ILD) - You had major surgery or radiation recently Talk to your doctor to see if this trial is right for you.